Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient

Transpl Infect Dis. 2020 Aug;22(4):e13326. doi: 10.1111/tid.13326. Epub 2020 Jun 5.

Authors

Sridhar R Allam^{1

2}, Ann Dao², Machaiah M Madhrira^{1

2}, Philip B Antiporta³, Ranjit R Nair⁴, Jacfranz J Guiteau², Ashraf I Reyad²

Affiliations

¹ Tarrant Nephrology Associates/Premier Physicians Group Health, Fort Worth, Texas, USA.
² Medical City Fort Worth Transplant Institute, Fort Worth, Texas, USA.
³ Infectious Disease Doctors, PA, Fort Worth, Texas, USA.
⁴ Lung & Sleep Center of North Texas, Fort Worth, Texas, USA.

No abstract available

Keywords: COVID-19; SARS-CoV-2; kidney transplant; tocilizumab.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use*
Betacoronavirus*
Biomarkers
COVID-19
Coronavirus Infections / diagnostic imaging
Coronavirus Infections / drug therapy*
Female
Humans
Inflammation / drug therapy
Kidney Transplantation
Pandemics
Pneumonia, Viral / diagnostic imaging
Pneumonia, Viral / drug therapy*
Receptors, Interleukin-6 / antagonists & inhibitors*
SARS-CoV-2
Transplant Recipients

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
Receptors, Interleukin-6
tocilizumab